Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Paolo Tarantino, Gabriele Antonarelli, Liliana Ascione & Giuseppe Curigliano. (2022) Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. Expert Opinion on Investigational Drugs 31:6, pages 499-513.
Read now
Read now
Chiara Corti, Eleonora Nicolò & Giuseppe Curigliano. (2021) Novel immune targets for the treatment of triple-negative breast cancer. Expert Opinion on Therapeutic Targets 25:10, pages 815-834.
Read now
Read now
Articles from other publishers (38)
Zahra Mokhtari, Marzieh Rezaei, Mohammad Hossein Sanei, Amirreza Dehghanian, Zahra Faghih, Zahra Heidari & Shirin Tavana. (2023) Tim3 and PD-1 as a therapeutic and prognostic targets in colorectal cancer: Relationship with sidedness, clinicopathological parameters, and survival. Frontiers in Oncology 13.
Crossref
Crossref
Sofia Valente, Catarina Nascimento, Andreia Gameiro, João Ferreira, Jorge Correia & Fernando Ferreira. (2023) TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma. Cancers 15:2, pages 384.
Crossref
Crossref
Pouya Mahdavi Sharif, Amin Pastaki Khoshbin, Elaheh Nasrollahzadeh, Mahsa Keshavarz-Fathi & Nima Rezaei. 2023. Clinical Immunology. Clinical Immunology
245
452
.
Gaia Griguolo, Anna Tosi, Maria Vittoria Dieci, Susan Fineberg, Valentina Rossi, Annavera Ventura, Michele Bottosso, Luc Bauchet, Federica Miglietta, Jack Jacob, Valerie Rigau, Matteo Fassan, William Jacot, PierFranco Conte, Antonio Rosato, Amelie Darlix & Valentina Guarneri. (2022) A comprehensive profiling of the immune microenvironment of breast cancer brain metastases. Neuro-Oncology 24:12, pages 2146-2158.
Crossref
Crossref
Elif Acar, Güldal Esendağlı, Ozan Yazıcı & Ayşe Dursun. (2022) Tumor-Infiltrating Lymphocytes (TIL), Tertiary Lymphoid Structures (TLS), and Expression of PD-1, TIM-3, LAG-3 on TIL in Invasive and In Situ Ductal Breast Carcinomas and Their Relationship with Prognostic Factors. Clinical Breast Cancer 22:8, pages e901-e915.
Crossref
Crossref
Alexander Rühle, Jovan Todorovic, Simon S. K. Spohn, Eleni Gkika, Christoph Becker, Andreas Knopf, Constantinos Zamboglou, Tanja Sprave, Martin Werner, Anca-Ligia Grosu, Gian Kayser & Nils H. Nicolay. (2022) Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy. Radiation Oncology 17:1.
Crossref
Crossref
Baran Mollavelioglu, Esin Cetin Aktas, Neslihan Cabioglu, Aykhan Abbasov, Semen Onder, Selman Emiroglu, Mustafa Tükenmez, Mahmut Muslumanoglu, Abdullah Igci, Gunnur Deniz & Vahit Ozmen. (2022) High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer. World Journal of Surgical Oncology 20:1.
Crossref
Crossref
Katsuhiro Yoshikawa, Mitsuaki Ishida, Hirotsugu Yanai, Koji Tsuta, Mitsugu Sekimoto & Tomoharu Sugie. (2022) Prognostic significance of the expression levels of T‑cell immunoglobulin mucin‑3 and its ligand galectin‑9 for relapse‑free survival in triple‑negative breast cancer. Oncology Letters 23:6.
Crossref
Crossref
Ombretta Melaiu, Valeria Lucarini, Roberto Giovannoni, Doriana Fruci & Federica Gemignani. (2022) News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Seminars in Cancer Biology 79, pages 18-43.
Crossref
Crossref
Elisabeth S. Stovgaard, Iben Kümler, Kamille List-jensen, Anne Roslind, Ib J. Christensen, Estrid Høgdall, Dorte Nielsen & Eva Balslev. (2022) Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer. Applied Immunohistochemistry & Molecular Morphology 30:1, pages 62-71.
Crossref
Crossref
Victor Sarradin, Amélie Lusque, Thomas Filleron, Florence Dalenc & Camille Franchet. (2021) Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study. Breast Cancer Research 23:1.
Crossref
Crossref
Neslihan Cabioglu, Semen Onder, Gizem Oner, Hüseyin Karatay, Mustafa Tukenmez, Mahmut Muslumanoglu, Abdullah İgci, Yeşim Eralp, Adnan Aydiner, Pınar Saip, Ekrem Yavuz & Vahit Ozmen. (2021) TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer. BMC Cancer 21:1.
Crossref
Crossref
Elham Masoumi, Sahar Tahaghoghi-Hajghorbani, Leila Jafarzadeh, Mohammad-Javad Sanaei, Atieh Pourbagheri-Sigaroodi & Davood Bashash. (2021) The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle. Journal of Controlled Release 340, pages 168-187.
Crossref
Crossref
Nazia Riaz, Samantha Burugu, Angela S. Cheng, Samuel C. Y. Leung, Dongxia Gao & Torsten O. Nielsen. (2021) Prognostic Significance of CSF-1R Expression in Early Invasive Breast Cancer. Cancers 13:22, pages 5769.
Crossref
Crossref
M. Kossai, N. Radosevic-Robin & F. Penault-Llorca. (2021) Refining patient selection for breast cancer immunotherapy: beyond PD-L1. ESMO Open 6:5, pages 100257.
Crossref
Crossref
Wenxiang Zhang, Xiangyi Kong, Bolun Ai, Zhongzhao Wang, Xiangyu Wang, Nianchang Wang, Shan Zheng, Yi Fang & Jing Wang. (2021) Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy. Frontiers in Oncology 11.
Crossref
Crossref
Karama Asleh, Nazia Riaz, Angela S. Cheng, Dongxia Gao, Samuel C. Y. Leung, Meenakshi Anurag & Torsten O. Nielsen. (2021) Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. npj Breast Cancer 7:1.
Crossref
Crossref
Yizi Cong, Jing Liu, Gang Chen & Guangdong Qiao. (2021) The Emerging Role of T-Cell Immunoglobulin Mucin-3 in Breast Cancer: A Promising Target For Immunotherapy. Frontiers in Oncology 11.
Crossref
Crossref
Yufan Qiu, Yi Yang, Riyao Yang, Chunxiao Liu, Jung-Mao Hsu, Zhou Jiang, Linlin Sun, Yongkun Wei, Chia-Wei Li, Dihua Yu, Jin Zhang & Mien-Chie Hung. (2021) Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. Oncogene 40:31, pages 4992-5001.
Crossref
Crossref
Fan Yang, Ziqing Zeng, Jing Li, Xiubao Ren & Feng Wei. (2021) TIM-3 and CEACAM1 are Prognostic Factors in Head and Neck Squamous Cell Carcinoma. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Karita Peltonen, Sara Feola, Husen M. Umer, Jacopo Chiaro, Georgios Mermelekas, Erkko Ylösmäki, Sari Pesonen, Rui M. M. Branca, Janne Lehtiö & Vincenzo Cerullo. (2021) Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy. Cancers 13:14, pages 3408.
Crossref
Crossref
Qiang Liu, Yihang Qi, Jie Zhai, Xiangyi Kong, Xiangyu Wang, Zhongzhao Wang, Yi Fang & Jing Wang. (2021) Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples. Frontiers in Immunology 12.
Crossref
Crossref
Min Hu, Yongfu Li, Yuting Lu, Miao Wang, Yingrui Li, Chaoying Wang, Qin Li & Hong Zhao. (2021) The regulation of immune checkpoints by the hypoxic tumor microenvironment. PeerJ 9, pages e11306.
Crossref
Crossref
Vincenzo Salemme, Giorgia Centonze, Federica Cavallo, Paola Defilippi & Laura Conti. (2021) The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Frontiers in Oncology 11.
Crossref
Crossref
Shawn C. Chafe, Nazia Riaz, Samantha Burugu, Dongxia Gao, Samuel C. Y. Leung, Anna F. Lee, Cheng-Han Lee, Shoukat Dedhar & Torsten O. Nielsen. (2021) Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune Checkpoints. Cancers 13:5, pages 1022.
Crossref
Crossref
Shafei Wu, Xiaohua Shi, Jing Wang, Xuefei Wang, Yuanyuan Liu, Yufeng Luo, Feng Mao & Xuan Zeng. (2021) Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3. Frontiers in Immunology 12.
Crossref
Crossref
Kui Zang, Liangliang Hui, Min Wang, Ying Huang, Xingxing Zhu & Bin Yao. (2021) TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinformatics Validation. Frontiers in Oncology 11.
Crossref
Crossref
Mei-Yin C. Polley, Roberto A. Leon-Ferre, Samuel Leung, Angela Cheng, Dongxia Gao, Jason Sinnwell, Heshan Liu, David W. Hillman, Abraham Eyman-Casey, Judith A. Gilbert, Vivian Negron, Judy C. Boughey, Minetta C. Liu, James N. Ingle, Krishna Kalari, Fergus Couch, Jodi M. Carter, Daniel W. Visscher, Torsten O. Nielsen & Matthew P. Goetz. (2021) A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Research and Treatment 185:3, pages 557-566.
Crossref
Crossref
Mona Sadeghalvad, Hamid-Reza Mohammadi-Motlagh & Nima Rezaei. (2020) Immune microenvironment in different molecular subtypes of ductal breast carcinoma. Breast Cancer Research and Treatment 185:2, pages 261-279.
Crossref
Crossref
Sahar Shariati, Atri Ghods, Mahshid Zohouri, Reza Rasolmali, Abdol-Rasoul Talei, Fereshteh Mehdipour & Abbas Ghaderi. (2020) Significance of TIM-3 expression by CD4+ and CD8+ T lymphocytes in tumor-draining lymph nodes from patients with breast cancer. Molecular Immunology 128, pages 47-54.
Crossref
Crossref
Mayanne M.T. Zhu, Samantha Burugu, Dongxia Gao, Jamie Yu, Zuzana Kos, Samuel Leung, Basil A. Horst & Torsten O. Nielsen. (2020) Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types. Modern Pathology 33:9, pages 1753-1763.
Crossref
Crossref
Liju Zong, Shengwei Mo, Shuangni Yu, Yuncan Zhou, Ming Zhang, Jie Chen & Yang Xiang. (2020) Expression of the immune checkpoint VISTA in breast cancer. Cancer Immunology, Immunotherapy 69:8, pages 1437-1446.
Crossref
Crossref
Huimin Du, Ziying Yi, Long Wang, Zhi Li, Bailin Niu & Guosheng Ren. (2020) The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy. International Immunopharmacology 78, pages 106113.
Crossref
Crossref
Angela S. Cheng, Samuel C. Y. Leung, Dongxia Gao, Samantha Burugu, Meenakshi Anurag, Matthew J. Ellis & Torsten O. Nielsen. (2019) Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. Breast Cancer Research and Treatment 179:1, pages 3-10.
Crossref
Crossref
Wenhua Li, Jingbo Qie, Yao Zhang & Jinjia Chang. 2020. Regulation of Cancer Immune Checkpoints. Regulation of Cancer Immune Checkpoints
167
200
.
Yu Wang, Qiyuan Kuai, Fenghua Gao, Yanbing Wang, Min He, Hong Zhou, Gencheng Han, Xingwei Jiang, Suping Ren & Qun Yu. (2019) Overexpression of TIM-3 in Macrophages Aggravates Pathogenesis of Pulmonary Fibrosis in Mice. American Journal of Respiratory Cell and Molecular Biology 61:6, pages 727-736.
Crossref
Crossref
Sebastian Chrétien, Ioannis Zerdes, Jonas Bergh, Alexios Matikas & Theodoros Foukakis. (2019) Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. Cancers 11:5, pages 628.
Crossref
Crossref
Walter M. Kim, Yu-Hwa Huang, Amit Gandhi & Richard S. Blumberg. (2019) CEACAM1 structure and function in immunity and its therapeutic implications. Seminars in Immunology 42, pages 101296.
Crossref
Crossref